AbbVie's Acquisitions Report Card Shows Investors Have a Reason to Worry About the Allergan Buyout

You can't predict the future by merely looking at the past. But the past does give clues that help us make educated guesses about what the future might hold.

AbbVie (NYSE: ABBV) announced in June that it plans to acquire Allergan (NYSE: AGN). Many immediately panned the deal as a $63 billion mistake. Others were more optimistic about the transaction. These views were primarily based on the acquisition's price tag and the known pros and cons for Allergan.